Team:Dundee/Implementation/realWorld
From 2014.igem.org
Aplochocka (Talk | contribs) |
|||
(26 intermediate revisions not shown) | |||
Line 18: | Line 18: | ||
<div class="jumbotron"> | <div class="jumbotron"> | ||
<h1>Real world</h1> | <h1>Real world</h1> | ||
- | <p class="lead">Taking | + | <p class="lead">Taking Its First Steps</p> |
</div> | </div> | ||
<div class="row"> | <div class="row"> | ||
Line 32: | Line 32: | ||
<div class="row"> | <div class="row"> | ||
- | <div class="col-xs-12"> | + | |
+ | <div class="row"> | ||
+ | |||
+ | <div class="col-xs-12"> | ||
<h2 id="0">User Feedback</h2> | <h2 id="0">User Feedback</h2> | ||
<p> | <p> | ||
- | Since the L.A.S.S.O. was designed using input from the CF community we wanted them let us know how well it worked. It was essential to the team that possible future users could use the prototype. Therefore, we took the L.A.S.S.O. back to the our local CF clinic in order to get possible future users to have a go at testing the device. | + | Since the L.A.S.S.O. was designed using input from the CF community we wanted them to let us know how well it worked. It was essential to the team that possible future users could use the prototype. Therefore, we took the L.A.S.S.O. back to the our local CF clinic in order to get possible future users to have a go at testing the device. |
+ | <br/> | ||
+ | <br/> | ||
+ | Michael, a Cystic Fibrosis patient, gives his view on the L.A.S.S.O.; | ||
+ | </p> | ||
+ | |||
+ | <video controls="controls" width=50% height=50% name="Video Name"> | ||
+ | <source src="https://2014.igem.org/File:DUN_Michael_and_the_Future_of_the_Lung_Ranger.ogg" type='video/ogg; codecs="theora, vorbis"'/> | ||
+ | <source src="https://static.igem.org/mediawiki/2014/a/ad/DUN_Michael_and_the_Future_of_the_Lung_Ranger.mov" type='video/mp4'/> | ||
+ | </video> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <div class="row"> | ||
+ | <div class="col-12"> | ||
+ | <p> | ||
+ | <br/> | ||
+ | <br/> | ||
+ | Dr Rogers giving her views on the L.A.S.S.O. Interface; | ||
</p> | </p> | ||
</div> | </div> | ||
Line 45: | Line 66: | ||
</div> | </div> | ||
<div class="col-10"> | <div class="col-10"> | ||
- | |||
<video controls="controls" width=50% height=50% name="Video Name" > | <video controls="controls" width=50% height=50% name="Video Name" > | ||
<source src="https://static.igem.org/mediawiki/2014/b/be/Dr_Rodgers_and_the_LASSO_Interface.ogg" type='video/ogg; codecs="theora, vorbis"'/> | <source src="https://static.igem.org/mediawiki/2014/b/be/Dr_Rodgers_and_the_LASSO_Interface.ogg" type='video/ogg; codecs="theora, vorbis"'/> | ||
<source src="https://static.igem.org/mediawiki/2014/a/a1/Dr_Rodgers_and_the_LASSO_Interface.mov" type='video/mp4'/> | <source src="https://static.igem.org/mediawiki/2014/a/a1/Dr_Rodgers_and_the_LASSO_Interface.mov" type='video/mp4'/> | ||
- | |||
- | |||
</video> | </video> | ||
</div> | </div> | ||
Line 56: | Line 74: | ||
</div> | </div> | ||
</div> | </div> | ||
- | |||
- | |||
<div class="row"> | <div class="row"> | ||
- | <div class="col- | + | <div class="col-12"> |
- | < | + | <p> |
- | + | ||
<br/> | <br/> | ||
- | < | + | </p> |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
</div> | </div> | ||
- | |||
</div> | </div> | ||
- | + | ||
- | + | ||
+ | |||
+ | <div class="row"> | ||
<div class="col-xs-12"> | <div class="col-xs-12"> | ||
<hr> | <hr> | ||
Line 129: | Line 140: | ||
</div> | </div> | ||
</div> | </div> | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
<!--END OF CONTENT--> | <!--END OF CONTENT--> | ||
</div> | </div> | ||
+ | </div> | ||
+ | </div> | ||
</div> | </div> | ||
Line 154: | Line 158: | ||
</div> | </div> | ||
<div class="btn-group"> | <div class="btn-group"> | ||
- | <a href="financial" class="btn btn-default toLesson">Next Lesson: | + | <a href="financial" class="btn btn-default toLesson">Next Lesson: Quantitative Impact</a> |
</div> | </div> | ||
</div> | </div> | ||
- | + | ||
</div> | </div> | ||
Line 176: | Line 180: | ||
$('.submenu li').addClass('hide'); | $('.submenu li').addClass('hide'); | ||
} | } | ||
- | + | }); | |
- | + | ||
- | }); | + | $( "#info" ).click( function() { |
+ | $('#welcomeNote').appendTo("body"); | ||
+ | $("#welcomeNote").modal(); | ||
+ | }); | ||
+ | |||
</script> | </script> | ||
</body> | </body> | ||
</html> | </html> | ||
+ | {{:Team:Dundee/Template/welcomeNoteSchool}} |
Latest revision as of 22:30, 17 October 2014
Real world
Taking Its First Steps
User Feedback
Since the L.A.S.S.O. was designed using input from the CF community we wanted them to let us know how well it worked. It was essential to the team that possible future users could use the prototype. Therefore, we took the L.A.S.S.O. back to the our local CF clinic in order to get possible future users to have a go at testing the device.
Michael, a Cystic Fibrosis patient, gives his view on the L.A.S.S.O.;
Dr Rogers giving her views on the L.A.S.S.O. Interface;
Audit
We had an ISO 13485 certified auditor look through our documentation for the L.A.S.S.O. and perform a mock audit to highlight any additional steps we could take to have a product that is as industry-ready as possible. In addition to receiving suggestions about how to improve our documentation (which have been acted upon) we were informed of the following:
In Europe, to obtain a CE mark there are three devices directives:
- Medical Device Directive
- Active Implantable Device Directive
- In Vitro Diagnostics (IVD) Directive
A product life cycle is split into stages:
- Proof of concept/Feasibility
- Optimisation
- Verification
- Validation
- Launch
- Post Market surveillance
- Withdrawal from the market/end-of-life
The audit concludes with some general questions on the use of the device. We have answered these below.
Q. Microbiological concerns – are the specimen receptacles single use? How long can they be stored before the bin needs to be emptied? Will all the samples be from the same patient?
A. The receptacles (plates containing our biological components) will be single use and will be emptied from the bin and disposed of following autoclaving on the day of use. The samples will not all necessarily be from the same patient, this will depend on the number of patients being visited in a day. Neither the team nor medical staff have identified any potential issues with this approach.
Q. How will consistency be maintained between device batches?
A. During the manufacture of our receptacles and prior to freeze-drying, each inoculum of our biological component will be measured carefully for optical density and a sample will be assayed for activity in the presence of a synthetic signalling molecule. The latter process would be scaled-down to the minimal reaction size required to give a significant result in order to be economically viable.
Q. What kind of shelf-life/in-use stability are you looking at for this device? How will it be transported and stored?
A. It is difficult to project a shelf–life for this device but based upon the simplicity of the majority of the hardware (plastic casings etc.), if the biennial maintenance checks suggested in our requirements document are carried out for the electronic components, this product will potentially be viable for many years before replacement becomes necessary.
Q. How can an operator check the test is working – will you provide calibrators or controls?
A. Both a positive and a negative control would be supplied with the device. The negative control would be a plate that was identical to all other receptacles except that it would contain no bacterial culture and thus would also function as a reference measurement. The positive control would be a source of light such as an LED which would give a reliable intensity and wavelength of light. The light source should be of a very low light level so that it would be consistent with the level of light produced by the luciferase. The latter could be built in to future versions of the L.A.S.S.O.